248 related articles for article (PubMed ID: 21867767)
61. Human soluble guanylate cyclase as a nitric oxide sensor for NO-signalling reveals a novel function of nitrite reductase.
Pan J; Xu Q; Lin YW; Zhong F; Tan X
Chem Commun (Camb); 2013 Aug; 49(67):7454-6. PubMed ID: 23864033
[TBL] [Abstract][Full Text] [Related]
62. A nitric oxide/cysteine interaction mediates the activation of soluble guanylate cyclase.
Fernhoff NB; Derbyshire ER; Marletta MA
Proc Natl Acad Sci U S A; 2009 Dec; 106(51):21602-7. PubMed ID: 20007374
[TBL] [Abstract][Full Text] [Related]
63. Soluble guanylyl cyclase activation by HMR-1766 (ataciguat) in cells exposed to oxidative stress.
Zhou Z; Pyriochou A; Kotanidou A; Dalkas G; van Eickels M; Spyroulias G; Roussos C; Papapetropoulos A
Am J Physiol Heart Circ Physiol; 2008 Oct; 295(4):H1763-71. PubMed ID: 18757489
[TBL] [Abstract][Full Text] [Related]
64. Receptor-controlled phosphorylation of alpha 1 soluble guanylyl cyclase enhances nitric oxide-dependent cyclic guanosine 5'-monophosphate production in pituitary cells.
Kostic TS; Andric SA; Stojilkovic SS
Mol Endocrinol; 2004 Feb; 18(2):458-70. PubMed ID: 14630997
[TBL] [Abstract][Full Text] [Related]
65. Heme-assisted S-nitrosation desensitizes ferric soluble guanylate cyclase to nitric oxide.
Fernhoff NB; Derbyshire ER; Underbakke ES; Marletta MA
J Biol Chem; 2012 Dec; 287(51):43053-62. PubMed ID: 23093402
[TBL] [Abstract][Full Text] [Related]
66. Activators and stimulators of soluble guanylate cyclase counteract myofibroblast differentiation of prostatic and dermal stromal cells.
Zenzmaier C; Kern J; Heitz M; Plas E; Zwerschke W; Mattesich M; Sandner P; Berger P
Exp Cell Res; 2015 Nov; 338(2):162-9. PubMed ID: 26410556
[TBL] [Abstract][Full Text] [Related]
67. Interfacial residues promote an optimal alignment of the catalytic center in human soluble guanylate cyclase: heterodimerization is required but not sufficient for activity.
Seeger F; Quintyn R; Tanimoto A; Williams GJ; Tainer JA; Wysocki VH; Garcin ED
Biochemistry; 2014 Apr; 53(13):2153-65. PubMed ID: 24669844
[TBL] [Abstract][Full Text] [Related]
68. Reduced vascular responses to soluble guanylyl cyclase but increased sensitivity to sildenafil in female rats with type 2 diabetes.
Goulopoulou S; Hannan JL; Matsumoto T; Ogbi S; Ergul A; Webb RC
Am J Physiol Heart Circ Physiol; 2015 Jul; 309(2):H297-304. PubMed ID: 25957216
[TBL] [Abstract][Full Text] [Related]
69. Soluble guanylyl cyclase activation improves progressive cardiac remodeling and failure after myocardial infarction. Cardioprotection over ACE inhibition.
Fraccarollo D; Galuppo P; Motschenbacher S; Ruetten H; Schäfer A; Bauersachs J
Basic Res Cardiol; 2014 Jul; 109(4):421. PubMed ID: 24907870
[TBL] [Abstract][Full Text] [Related]
70. Alterations in soluble guanylate cyclase content and modulation by nitric oxide in liver disease.
Rodrigo R; Montoliu C; Chatauret N; Butterworth R; Behrends S; Del Olmo JA; Serra MA; Rodrigo JM; Erceg S; Felipo V
Neurochem Int; 2004 Nov; 45(6):947-53. PubMed ID: 15312989
[TBL] [Abstract][Full Text] [Related]
71. A real-time fluorescent assay of the purified nitric oxide receptor, guanylyl cyclase.
Newton M; Niewczas I; Clark J; Bellamy TC
Anal Biochem; 2010 Jul; 402(2):129-36. PubMed ID: 20371357
[TBL] [Abstract][Full Text] [Related]
72. Nitric oxide-independent vasodilator rescues heme-oxidized soluble guanylate cyclase from proteasomal degradation.
Meurer S; Pioch S; Pabst T; Opitz N; Schmidt PM; Beckhaus T; Wagner K; Matt S; Gegenbauer K; Geschka S; Karas M; Stasch JP; Schmidt HH; Müller-Esterl W
Circ Res; 2009 Jul; 105(1):33-41. PubMed ID: 19478201
[TBL] [Abstract][Full Text] [Related]
73. Role of sulfhydryl-dependent dimerization of soluble guanylyl cyclase in relaxation of porcine coronary artery to nitric oxide.
Zheng X; Ying L; Liu J; Dou D; He Q; Leung SW; Man RY; Vanhoutte PM; Gao Y
Cardiovasc Res; 2011 Jun; 90(3):565-72. PubMed ID: 21248051
[TBL] [Abstract][Full Text] [Related]
74. Role of the nitric oxide-soluble guanylyl cyclase pathway in obstructive airway diseases.
Dupont LL; Glynos C; Bracke KR; Brouckaert P; Brusselle GG
Pulm Pharmacol Ther; 2014 Oct; 29(1):1-6. PubMed ID: 25043200
[TBL] [Abstract][Full Text] [Related]
75. Loss of α1β1 soluble guanylate cyclase, the major nitric oxide receptor, leads to moyamoya and achalasia.
Hervé D; Philippi A; Belbouab R; Zerah M; Chabrier S; Collardeau-Frachon S; Bergametti F; Essongue A; Berrou E; Krivosic V; Sainte-Rose C; Houdart E; Adam F; Billiemaz K; Lebret M; Roman S; Passemard S; Boulday G; Delaforge A; Guey S; Dray X; Chabriat H; Brouckaert P; Bryckaert M; Tournier-Lasserve E
Am J Hum Genet; 2014 Mar; 94(3):385-94. PubMed ID: 24581742
[TBL] [Abstract][Full Text] [Related]
76. Soluble guanylyl cyclase: more secrets revealed.
Pyriochou A; Papapetropoulos A
Cell Signal; 2005 Apr; 17(4):407-13. PubMed ID: 15601619
[TBL] [Abstract][Full Text] [Related]
77. Nucleotide regulation of soluble guanylate cyclase substrate specificity.
Derbyshire ER; Fernhoff NB; Deng S; Marletta MA
Biochemistry; 2009 Aug; 48(31):7519-24. PubMed ID: 19527054
[TBL] [Abstract][Full Text] [Related]
78. Effects of chronic hypoxia on soluble guanylate cyclase activity in fetal and adult ovine cerebral arteries.
Pearce WJ; Williams JM; White CR; Lincoln TM
J Appl Physiol (1985); 2009 Jul; 107(1):192-9. PubMed ID: 19407253
[TBL] [Abstract][Full Text] [Related]
79. Differentiation of cGMP-dependent and -independent nitric oxide effects on platelet apoptosis and reactive oxygen species production using platelets lacking soluble guanylyl cyclase.
Rukoyatkina N; Walter U; Friebe A; Gambaryan S
Thromb Haemost; 2011 Nov; 106(5):922-33. PubMed ID: 21800013
[TBL] [Abstract][Full Text] [Related]
80. A novel insight into the molecular mechanism of human soluble guanylyl cyclase focused on catalytic domain in living cells.
Li J; Zhou Y; Lin YW; Tan X
Biochem Biophys Res Commun; 2022 May; 604():51-56. PubMed ID: 35290760
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
